China Pharma Holdings
CPHI
9 hedge funds and large institutions have $537K invested in China Pharma Holdings in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% more funds holding
Funds holding: 9 → 9 (0)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
20% less capital invested
Capital invested by funds: $670K → $537K (-$133K)
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$38.1K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$7.35K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.17K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.04K |
Top Sellers
| 1 |
PAM
Pope Asset Management
Memphis,
Tennessee
|
-$96.9K |
| 2 |
Bank of New York Mellon
New York
|
-$6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.05K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAM
1
Pope Asset Management
Memphis,
Tennessee
| $384K | -$96.9K | -857 | -20% |
|
|
2
Renaissance Technologies
New York
| $78K | +$38.1K | +337 | +99% |
|
|
GA
3
Glenhill Advisors
New York
| $46K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $8K | -$3.05K | -27 | -29% |
|
|
VKH
5
Virtu KCG Holdings
New York
| $8K | +$7.35K | +65 | New |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $6K | +$3.17K | +28 | +122% |
|
|
7
UBS Group
Zurich,
Switzerland
| $3K | +$2.04K | +18 | +200% |
|
8
Goldman Sachs
New York
| $2K | – | – | – |
|
|
PCM
9
Parsons Capital Management
Providence,
Rhode Island
| $2K | – | – | – |
|
|
10
Bank of New York Mellon
New York
| – | -$6K | -48 | Closed |
|
CPHI Hedge Fund Activity: Q2 2017 in Review
9 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in China Pharma Holdings (CPHI) for Q2 2017, worth a combined $537K — down 20% from $670K a quarter earlier.
Fund positioning in CPHI was balanced in Q2 2017: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $38.1K. The largest seller was Pope Asset Management, cutting an estimated $96.9K.
- 9 institutional investors held China Pharma Holdings (CPHI) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $537K of China Pharma Holdings stock for Q2 2017, down 20% quarter-over-quarter.
- 1 fund opened new China Pharma Holdings positions in Q2 2017 and 1 closed out, a net change of 0 holders.
- The largest China Pharma Holdings buyer in Q2 2017 was Renaissance Technologies, an estimated $38.1K added.
- The largest China Pharma Holdings seller in Q2 2017 was Pope Asset Management, an estimated $96.9K sold.
Based on aggregated 13F filings for Q2 2017.